US Drug Recall Register

FDA Drug Recalls

14,801 recalls, newest first

Risk Class IClass IIClass III
Status OngoingCompletedTerminated
Year 2026202520242023
Class II · Moderate risk Terminated

Montelukast Sodium Tablets

Reason CGMP Deviations: recalling drug products following an FDA inspection.

Accord Healthcare, Inc. NDC 16729-119-10 D-0400-2023
Class II · Moderate risk Terminated

Glycopyrrolate Injection

Reason CGMP Deviations: recalling drug products following an FDA inspection.

Accord Healthcare, Inc. NDC 16729-474-05 D-0399-2023
Class II · Moderate risk Terminated

Glycopyrrolate Injection

Reason CGMP Deviations: recalling drug products following an FDA inspection.

Accord Healthcare, Inc. NDC 16729-473-31 D-0398-2023
Class II · Moderate risk Terminated

Glycopyrrolate Injection

Reason CGMP Deviations: recalling drug products following an FDA inspection.

Accord Healthcare, Inc. NDC 16729-472-30 D-0397-2023
Class II · Moderate risk Terminated

Glycopyrrolate Injection

Reason CGMP Deviations: recalling drug products following an FDA inspection.

Accord Healthcare, Inc. NDC 16729-471-63 D-0396-2023
Class II · Moderate risk Terminated

Glimepiride Tablets USP

Reason CGMP Deviations: recalling drug products following an FDA inspection.

Accord Healthcare, Inc. NDC 16729-003-01 D-0395-2023
Class II · Moderate risk Terminated

Glimepiride Tablets USP

Reason CGMP Deviations: recalling drug products following an FDA inspection.

Accord Healthcare, Inc. NDC 16729-002-01 D-0394-2023
Class II · Moderate risk Terminated

Glimepiride Tablets USP

Reason CGMP Deviations: recalling drug products following an FDA inspection.

Accord Healthcare, Inc. NDC 16729-001-01 D-0393-2023
Class II · Moderate risk Terminated

Finasteride Tablets USP

Reason CGMP Deviations: recalling drug products following an FDA inspection.

Accord Healthcare, Inc. NDC 16729-090-10 D-0392-2023
Class II · Moderate risk Terminated

Finasteride Tablets USP 1 mg

Reason CGMP Deviations: recalling drug products following an FDA inspection.

Accord Healthcare, Inc. NDC 71713-096-90 D-0391-2023
Class II · Moderate risk Terminated

Finasteride Tablets USP

Reason CGMP Deviations: recalling drug products following an FDA inspection.

Accord Healthcare, Inc. NDC 16729-089-10 D-0390-2023
Class II · Moderate risk Terminated

Doxazosin Tablets USP

Reason CGMP Deviations: recalling drug products following an FDA inspection.

Accord Healthcare, Inc. NDC 16729-415-01 D-0389-2023
Class II · Moderate risk Terminated

Doxazosin Tablets USP

Reason CGMP Deviations: recalling drug products following an FDA inspection.

Accord Healthcare, Inc. NDC 16729-213-01 D-0388-2023
Class II · Moderate risk Terminated

Doxazosin Tablets USP

Reason CGMP Deviations: recalling drug products following an FDA inspection.

Accord Healthcare, Inc. NDC 16729-414-01 D-0387-2023
Class II · Moderate risk Terminated

Doxazosin Tablets USP 1 mg

Reason CGMP Deviations: recalling drug products following an FDA inspection.

Accord Healthcare, Inc. NDC 16729-211-01 D-0386-2023
Class II · Moderate risk Terminated

Dofetilide Capsules 500 mcg

Reason CGMP Deviations: recalling drug products following an FDA inspection.

Accord Healthcare, Inc. NDC 16729-492-12 D-0385-2023
Class II · Moderate risk Terminated

Dofetilide Capsules 250 mcg

Reason CGMP Deviations: recalling drug products following an FDA inspection.

Accord Healthcare, Inc. NDC 16729-491-12 D-0384-2023
Class II · Moderate risk Terminated

Dofetilide Capsules

Reason CGMP Deviations: recalling drug products following an FDA inspection.

Accord Healthcare, Inc. NDC 16729-490-12 D-0383-2023
Class II · Moderate risk Terminated

Daptomycin for Injection 500 mg per vial

Reason CGMP Deviations: recalling drug products following an FDA inspection.

Accord Healthcare, Inc. NDC 16729-435-05 D-0382-2023
Class II · Moderate risk Terminated

Daptomycin for Injection 350 mg/vial

Reason CGMP Deviations: recalling drug products following an FDA inspection.

Accord Healthcare, Inc. NDC 16729-434-05 D-0381-2023
Class II · Moderate risk Terminated

Clopidogrel Tablets USP

Reason CGMP Deviations: recalling drug products following an FDA inspection.

Accord Healthcare, Inc. NDC 16729-218-10 D-0380-2023
Class II · Moderate risk Terminated

BusPIRone Hydrochloride Tablets USP 30 mg

Reason CGMP Deviations: recalling drug products following an FDA inspection.

Accord Healthcare, Inc. NDC 16729-289-12 D-0379-2023
Class II · Moderate risk Terminated

BusPIRone Hydrochloride Tablets USP

Reason CGMP Deviations: recalling drug products following an FDA inspection.

Accord Healthcare, Inc. NDC 16729-202-16 D-0378-2023
Class II · Moderate risk Terminated

BusPIRone Hydrochloride Tablets USP 15 mg

Reason CGMP Deviations: recalling drug products following an FDA inspection.

Accord Healthcare, Inc. NDC 16729-203-01 D-0377-2023
Class II · Moderate risk Terminated

BusPIRone Hydrochloride Tablets USP

Reason CGMP Deviations: recalling drug products following an FDA inspection.

Accord Healthcare, Inc. NDC 16729-200-01 D-0376-2023